The study will use data from the ALZ-NET registry, which is expected to include about 20,000 patients being evaluated for- or treated with- new FDA-approved AD therapies. About 6,700 (33%) of these patients are expected to be treated with LEQEMBI.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Enrolled in ALZ-NET
Either currently receiving or previously received lecanemab-irmb.
